First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial
Marion Thibaudin(Centre Georges François Leclerc), François Ghiringhelli(Inserm)
Cited by 104
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells
|Journal of Clinical Investigation|2010|985
CD4<b>+</b>CD25<b>+</b> regulatory T cells inhibit natural killer cell functions in a transforming growth factor–β–dependent manner
|The Journal of Experimental Medicine|2005|918
Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer
|Nature Medicine|2022|637
Classification of current anticancer immunotherapies
|Oncotarget|2014|469